Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies-Reference-Cited by-同舟云学术

Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies

Published:2015-07-29 Issue:2 Volume:56 Page:143-151
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Liu Lichuan¹,Bello Akintunde²,Dresser Mark J.¹,Heald Donald³,Komjathy Steven Ferenc⁴,O'Mara Edward⁵,Rogge Mark⁶,Stoch S. Aubrey⁷,Robertson Sarah M.⁸

Affiliation:

1. Genentech Inc.; South San Francisco CA USA

2. Bristol-Myers Squibb; Princeton NJ USA

3. Janssen Research and Development; Spring House PA USA

4. Eli Lilly and Company; Indianapolis IN USA

5. Celgene Corp.; Summit NJ USA

6. Biogen, Inc.; Cambridge MA USA

7. Merck Sharp & Dohme Corp.; Lansdale PA USA

8. Vertex Pharmaceuticals Inc.; Boston MA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference45 articles.

1. Ketoconazole: an orally effective antifungal agent. Mechanism of action, pharmacology, clinical efficacy and adverse effects;Smith;Pharmacotherapy.,1984

2. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm

3. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&mid=WC0b01ac058004d5c1

4. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression;Gibbs;Drug Metab Dispos.,1999

5. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study;Zhao;J Clin Pharmacol.,2009

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An open‐label study to explore the optimal design of CYP3A drug–drug interaction clinical trials in healthy Chinese people;Pharmacology Research & Perspectives;2024-07-28

2. The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239;Clinical and Translational Science;2024-07

3. Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants;Antimicrobial Agents and Chemotherapy;2024-05-17

4. Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study;Marine Drugs;2024-04-16

5. The Impact of Drug Interactions with Tyrosine Kinase Inhibitors on Adverse Event Development based on the changes of drug concentration level: Meta-analysis;Korean Journal of Clinical Pharmacy;2024-03-31